Circulating antibodies against MAA adducts as biomarker for coronary artery disease
AssigneeBoard of Regents of the University of Nebraska
InventorsGeoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
Life of this patent
Estimating the term…
Abstract
In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldheyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
Claims12
A method of treating a mammal, said method comprising:
- i) identifying a mammal having an elevated level of IgG antibodies and/or IgM antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) as compared to the level found in a normal healthy mammal, and a level of IgA antibodies that bind an MAA adduct comparable to or lower than the levels found in a normal healthy mammal;
- and
- treating said mammal for unstable angina;
- or
- ii) identifying a mammal having an elevated level of IgG antibodies and/or IgM antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) as compared to the level found in a normal healthy mammal, and a level of IgA antibodies that bind an MAA adduct elevated as compared to that found in a normal healthy mammal and/or an acute myocardial infarction (AMI) patient;
- and
- treating said mammal for a stable angina.
Dependencies are inferred from the claim text.